NZ595630A - Methods for preventing and/or treating degenerative disorders of the central nervous system - Google Patents

Methods for preventing and/or treating degenerative disorders of the central nervous system

Info

Publication number
NZ595630A
NZ595630A NZ595630A NZ59563010A NZ595630A NZ 595630 A NZ595630 A NZ 595630A NZ 595630 A NZ595630 A NZ 595630A NZ 59563010 A NZ59563010 A NZ 59563010A NZ 595630 A NZ595630 A NZ 595630A
Authority
NZ
New Zealand
Prior art keywords
nervous system
central nervous
preventing
methods
degenerative disorders
Prior art date
Application number
NZ595630A
Other languages
English (en)
Inventor
Robert Boyd
Gary Lee
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of NZ595630A publication Critical patent/NZ595630A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ595630A 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system NZ595630A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16810109P 2009-04-09 2009-04-09
PCT/US2010/030470 WO2010118282A1 (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Publications (1)

Publication Number Publication Date
NZ595630A true NZ595630A (en) 2013-04-26

Family

ID=42934882

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595630A NZ595630A (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Country Status (11)

Country Link
US (1) US8304429B2 (https=)
EP (1) EP2416655B1 (https=)
JP (1) JP5634498B2 (https=)
CN (1) CN102448306B (https=)
AU (1) AU2010233187B2 (https=)
BR (1) BRPI1015472A2 (https=)
CA (1) CA2758187C (https=)
ES (1) ES2505243T3 (https=)
IL (1) IL215584A (https=)
NZ (1) NZ595630A (https=)
WO (1) WO2010118282A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1010517A2 (pt) * 2009-04-09 2017-01-31 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
SI2995306T1 (sl) * 2009-10-19 2019-04-30 Amicus Therapeutics, Inc. Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja
KR101880411B1 (ko) 2009-10-19 2018-07-19 아미쿠스 세라퓨틱스, 인코포레이티드 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
CA2817960C (en) 2010-11-17 2020-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2013070981A2 (en) * 2011-11-08 2013-05-16 University Of Central Florida Research Foundation, Inc. Treating er stress related disorders by stabilizing intracellular calcium homeostasis
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US9796680B2 (en) 2013-12-23 2017-10-24 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN110177572A (zh) * 2016-09-12 2019-08-27 史蒂文·霍夫曼 用于治疗痴呆的组合物
BR112018014281A2 (pt) * 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
SG11202006528XA (en) 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN120310791A (zh) 2018-01-12 2025-07-15 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
CN119606967B (zh) * 2024-12-13 2025-09-05 合肥工业大学 氯雷他定在制备用于预防和治疗血管钙化药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243196T1 (de) * 1994-03-09 2003-07-15 Novo Nordisk As Piperidine und pyrrolidine
US20060079533A1 (en) * 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6670625B1 (en) * 2002-06-18 2003-12-30 Ge Medical Systems Global Technology Company, Llc Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner
EP1558245A2 (en) * 2002-10-28 2005-08-03 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
WO2007150064A2 (en) 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
US20080009156A1 (en) 2006-07-10 2008-01-10 Malin Glen K System and method for bonding coaxial cable
BRPI1010517A2 (pt) * 2009-04-09 2017-01-31 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal

Also Published As

Publication number Publication date
EP2416655A4 (en) 2012-09-05
AU2010233187A1 (en) 2011-11-03
EP2416655A1 (en) 2012-02-15
IL215584A0 (en) 2011-12-29
BRPI1015472A2 (pt) 2015-11-24
JP5634498B2 (ja) 2014-12-03
JP2012523430A (ja) 2012-10-04
ES2505243T3 (es) 2014-10-09
US20100261753A1 (en) 2010-10-14
IL215584A (en) 2016-11-30
EP2416655B1 (en) 2014-06-25
CN102448306B (zh) 2014-07-02
AU2010233187B2 (en) 2015-10-08
CA2758187A1 (en) 2010-10-14
HK1168005A1 (zh) 2012-12-21
US8304429B2 (en) 2012-11-06
CA2758187C (en) 2017-03-07
CN102448306A (zh) 2012-05-09
WO2010118282A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
NZ595630A (en) Methods for preventing and/or treating degenerative disorders of the central nervous system
NZ595629A (en) Methods for preventing and/or treating lysosomal storage disorders
NZ598145A (en) Folate-targeted diagnostics and treatment
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MY162067A (en) Combination therapy for treatment of patients with neurological disorders and cerebral infarction
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY199027A (en) Method for treating or preventing ophthalmological conditions
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
EP2521592A4 (en) INTENSITY-MODULATED ROTATION THERAPY WITH CONTINUOUS BED ROTATION / SHIFTING AND SIMULTANEOUS 3D IMAGING
PH12014500239A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
UA98136C2 (ru) Применение аклидиния для лечения респираторных заболеваний
WO2011009020A3 (en) Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
MX2012007813A (es) Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional.
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
BR112016020381A8 (pt) sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina.
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
MY196979A (en) Method of treating disease by auricular anesthesia of cranial nerves
WO2011050008A9 (en) Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
MX2013006564A (es) Uso de dronedarona para la preparacion de un farmaco para uso en la gestion del riesgo de daño hpatico.

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE AGENT HAS BEEN CORRECTED TO 1441794, IPONZ, 2. , 205 VICTORIA STREET, TE ARO, WELLINGTON 6011, NZ; 1028818, WRAYS, WRAYS #1701, 24B MOOREFIELD ROAD, JOHNSONVILLE, WELLINGTON 6037, NZ

Effective date: 20130404

Free format text: THE AGENT HAS BEEN CORRECTED TO 1028818, WRAYS, WRAYS #1701, 24B MOOREFIELD ROAD, JOHNSONVILLE, WELLINGTON 6037, NZ

Effective date: 20130404

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 APR 2017 BY CPA GLOBAL

Effective date: 20140306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2018 BY CPA GLOBAL

Effective date: 20170303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2019 BY CPA GLOBAL

Effective date: 20180301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2020 BY CPA GLOBAL

Effective date: 20190307

LAPS Patent lapsed